FDA panel endorses Novo's liraglutide in weight loss
This article was originally published in Scrip
Executive Summary
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) on 11 September voted 14-1 that the overall benefit-risk assessment of Novo Nordisk's glucagon-like-peptide (GLP-1) receptor agonist liraglutide at the 3mg per day dosage supported its approval as a weight loss therapy.